Strategies to Increase Cervical Cancer Screening With Mailed Human Papillomavirus Self-Sampling Kits: A Randomized Clinical Trial

被引:10
|
作者
Winer, Rachel L. [1 ,2 ]
Lin, John [1 ]
Anderson, Melissa L. [2 ]
Tiro, Jasmin A. [3 ]
Green, Beverly B. [2 ,4 ]
Gao, Hongyuan [2 ]
Meenan, Richard T. [5 ]
Hansen, Kristina [2 ]
Sparks, Angela [6 ,7 ,8 ]
Buist, Diana S. M. [1 ,9 ]
机构
[1] Univ Washington, Dept Epidemiol, 3980 15th Ave NE,Box 351619, Seattle, WA 98195 USA
[2] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA
[3] Univ Chicago, Biol Sci Div, Dept Publ Hlth Sci, Chicago, IL 60637 USA
[4] Kaiser Permanente Bernard J Tyson Sch Med, Dept Hlth Syst Sci, Pasadena, CA USA
[5] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA
[6] Washington Permanente Med Grp, Seattle, WA USA
[7] Washington Permanente Med Grp, Seatac, WA USA
[8] UnitedHealthcare Community Plan Washington, Seatac, WA USA
[9] GRAIL LLC, Menlo Pk, CA USA
来源
基金
美国国家卫生研究院;
关键词
WOMEN; BARRIERS;
D O I
10.1001/jama.2023.21471
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Optimal strategies for increasing cervical cancer screening may differ by patient screening history and health care setting. Mailing human papillomavirus (HPV) self-sampling kits to individuals who are overdue for screening increases adherence; however, offering self-sampling kits to screening-adherent individuals has not been evaluated in the US. OBJECTIVE To evaluate the effectiveness of direct-mail and opt-in approaches for offering HPV self-sampling kits to individuals by cervical cancer screening history (screening-adherent and currently due, overdue, or unknown). DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial conducted in Kaiser Permanente Washington, a US integrated health care delivery system. Individuals aged 30 to 64 years with female sex, a primary care clinician, and no hysterectomy were identified through electronic health records (EHRs) and enrolled between November 20, 2020, and January 28, 2022, with follow-up through July 29, 2022. INTERVENTIONS Individuals stratified as due (eg, at the time of randomization, these individuals have been previously screened and are due for their next screening in <= 3 months) were randomized to receive usual care (patient reminders and clinician EHR alerts [n=3671]), education (usual care plus educational materials about screening [n=3960]), direct mail (usual care plus educational materials and a mailed self-sampling kit [n=1482]), or to opt in (usual care plus educational materials and the option to request a kit [n=3956]). Individuals who were overdue for screening were randomized to receive usual care (n=5488), education (n=1408), or direct mail (n=1415). Individuals with unknown history for screening were randomized to receive usual care (n=2983), education (n=3486), or to opt in (n=3506). MAIN OUTCOMES AND MEASURES The primary outcome was screening completion within 6 months. Primary analyses compared direct-mail or opt-in participants with individuals randomized to the education group. RESULTS The intention-to-treat analyses included 31355 randomized individuals (mean [SD] age, 45.9 [10.4] years). Among those who were due for screening, compared with receiving education alone (1885 [47.6%]), screening completion was 14.1% (95% CI, 11.2%-16.9%) higher in the direct-mail group (914 [61.7%]) and 3.5% (95% CI, 1.2%-5.7%) higher in the opt-in group (2020 [51.1%]). Among individuals who were overdue, screening completion was 16.9% (95% CI, 13.8%-20.0%) higher in the direct-mail group (505 [35.7%]) compared with education alone (264 [18.8%]). Among those with unknown history, screening was 2.2% (95% CI, 0.5%-3.9%) higher in the opt-in group (634 [18.1%]) compared with education alone (555 [15.9%]). CONCLUSIONS AND RELEVANCE Within a US health care system, direct-mail self-sampling increased cervical cancer screening by more than 14% in individuals who were due or overdue for cervical cancer screening. The opt-in approach minimally increased screening. To increase screening adherence, systems implementing HPV self-sampling should prioritize direct-mail outreach for individuals who are due or overdue for screening. For individuals with unknown screening history, testing alternative outreach approaches and additional efforts to document screening history are warranted.
引用
收藏
页码:1971 / 1981
页数:11
相关论文
共 50 条
  • [31] Effectiveness and feasibility of self-sampling for human papillomavirus testing for internet-based cervical cancer screening
    Li, Jingran
    Wu, Ruifang
    Qu, Xinfeng
    Huang, Xia
    Li, Ling
    Lin, Zhixin
    Zhang, Zhijun
    Deng, Jihong
    Liu, Rong
    Zhao, Xiaofeng
    Zhang, Songling
    Lin, Bei
    An, Ruifang
    Zhao, Chao
    Li, Mingzhu
    Zhao, Yun
    Wei, Lihui
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [32] Primary cervical cancer screening by self-sampling of human papillomavirus DNA in internal medicine outpatient clinics
    Dannecker, C
    Siebert, U
    Thaler, CJ
    Kiermeir, D
    Hepp, H
    Hillemanns, P
    ANNALS OF ONCOLOGY, 2004, 15 (06) : 863 - 869
  • [33] The potential role of self-sampling for high-risk human papillomavirus detection in cervical cancer screening
    Schmeink, Channa E.
    Bekkers, Ruud L. M.
    Massuger, Leon F. A. G.
    Melchers, Willem J. G.
    REVIEWS IN MEDICAL VIROLOGY, 2011, 21 (03) : 139 - 153
  • [34] Vaginal Self-Sampling for Human Papillomavirus Infection as a Primary Cervical Cancer Screening Tool in a Haitian Population
    Boggan, Joel C.
    Walmer, David K.
    Henderson, Gregory
    Chakhtoura, Nahida
    McCarthy, Schatzi H.
    Beauvais, Harry J.
    Smith, Jennifer S.
    SEXUALLY TRANSMITTED DISEASES, 2015, 42 (11) : 655 - 659
  • [35] HPV self-sampling in cervical cancer screening: the effect of different invitation strategies in various socioeconomic groups - a randomized controlled trial
    Tranberg, Mette
    Bech, Bodil Hammer
    Blaakaer, Jan
    Jensen, Jorgen Skov
    Svanholm, Hans
    Andersen, Berit
    CLINICAL EPIDEMIOLOGY, 2018, 10 : 1027 - 1036
  • [36] Self-sampling tools to increase cancer screening among underserved patients: a pilot randomized controlled trial
    Moss, Jennifer L.
    Entenman, Juliette
    Stoltzfus, Kelsey
    Liao, Jiangang
    Onega, Tracy
    Reiter, Paul L.
    Klesges, Lisa M.
    Garrow, George
    Ruffin, Mack T.
    JNCI CANCER SPECTRUM, 2024, 8 (01)
  • [37] Co-creation of human papillomavirus self-sampling delivery strategies for cervical cancer screening in rural Zimbabwe: nominal group technique
    Dzobo, Mathias
    Dzinamarira, Tafadzwa
    Murewanhema, Grant
    Chishapira, Tatenda
    Mandishora, Racheal S. Dube
    Fitzpatrick, Megan
    Mashamba-Thompson, Tivani
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [38] Randomized trial evaluating self-sampling for HPV DNA based tests for cervical cancer screening in Nigeria
    Modibbo, Fatima
    Iregbu, K. C.
    Okuma, James
    Leeman, Annemiek
    Kasius, Annemieke
    de Koning, Maurits
    Quint, Wim
    Adebamowo, Clement
    INFECTIOUS AGENTS AND CANCER, 2017, 12 : 1 - 9
  • [39] Randomized trial evaluating self-sampling for HPV DNA based tests for cervical cancer screening in Nigeria
    Fatima Modibbo
    K. C. Iregbu
    James Okuma
    Annemiek Leeman
    Annemieke Kasius
    Maurits de Koning
    Wim Quint
    Clement Adebamowo
    Infectious Agents and Cancer, 12
  • [40] COST-EFFECTIVENESS ANALYSIS OF CERVICAL CANCER SCREENING WITH SELF-SAMPLING FOR HUMAN PAPILLOMAVIRUS (HPV) TESTING IN TAIWAN
    Tsai, B. C.
    Chow, I. H. I.
    Liao, C. H.
    You, S. L.
    Tang, C. H.
    Pwu, R. F.
    VALUE IN HEALTH, 2012, 15 (07) : A656 - A657